Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationArticle Published on 2022-10-172023-07-08 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] AZD1222 COVID-19 mRNA vaccine omicron third dose [DOI] 10.1093/infdis/jiac092
Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary?그리스의 면역 저하 성인에서 SARS-CoV-2 BNT162b2 백신 3차 접종 후 항체 역가: 4차 접종이 필요한가요?Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age anti-S Anti-spike antibody Antibody titers Autoimmune autoimmune diabete autoimmune diabetes Autoimmune disease average baseline BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BNT162b2 vaccine change correlated COVID-19 Decline decrease diabetes dose Effectiveness fold Fold change Fold changes Greece humoral Humoral response IgG antibody titer IgG antibody titers IgG GMC Immunocompromised immunocompromised adult immunocompromised adults immunocompromised individual immunocompromised individuals immunogenicity Inflammatory inflammatory disease leukemia lymphoma mRNA of BNT162b2 Omicron variant Omicron variants postvaccination real-world data SARS-CoV-2 serum sample serum samples Sex significantly the SARS-CoV-2 the vaccine third dose vaccination Vaccine vaccine dose vulnerable population [DOI] 10.1002/jmv.27954 PMC 바로가기 [Article Type] Article
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concernArticle Published on 2022-10-012022-11-15 Journal: ESMO open [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Anti-spike antibody BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine BNT162b2 vaccine booster Cancer cancer patient cell-mediated immune Cellular immune response Concentration COVID-19 delta variant dose evaluated follow-up period highest highlight Hospitalization humoral Immunoglobulin Infection interferon-γ interquartile range longitudinal cohort study lowest median Messenger RNA Neutralizing Neutralizing activity neutralizing antibody of BNT162b2 omicron Oxygen therapy Patient positive response reduced reduction in required SARS-CoV-2 serum Seven solid tumor subject the SARS-CoV-2 third dose Treatment triggering Vaccine variant variants of concern VOCs were measured were used whole blood sample wild-type strain [DOI] 10.1016/j.esmoop.2022.100574 PMC 바로가기
Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional surveyArticle Published on 2022-09-142022-11-16 Journal: BMC Public Health [Category] SARS, 변종, [키워드] Analysis Annual benefit booster dose chronic conducted COVID-19 COVID-19 disease COVID-19 vaccine cross-sectional cross-sectional survey determine dose doses Effectiveness facilitate Factor Factors Government higher education higher odd identify identity immunization increasing age Infection influences on Influenza influenza vaccine Intention multinomial logistic regression National new SARS-CoV-2 Offering Pharmacy populations preference primary dose receive recommendation refusal reported required seasonal Sociodemographic targeted intervention third dose transition vaccination Vaccine vaccine dose variants waning immunity were used widespread [DOI] 10.1186/s12889-022-14025-8 PMC 바로가기
Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipientsArticle Published on 2022-09-022022-11-15 Journal: European journal of cardio-thoracic surgery : official journal of the [Category] 진단, 치료제, [키워드] acute respiratory syndrome age Anti-spike association baseline BNT162b2 BNT162b2 vaccine booster coronavirus COVID-19 decrease dose General population heart Heart transplantation immunogenicity Immunoglobulin Improved inhibitor inhibitors IQR lack mammalian median age mRNA vaccine non-responder of BNT162b2 oral steroid Patient positive predictor proportion prospective cohort study Rapamycin recipient recipients Responder seropositive Serum level severe acute respiratory syndrome coronavirus 2 significantly significantly increased the median third dose titre U/mL Vaccine [DOI] 10.1093/ejcts/ezac145 PMC 바로가기
Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third doseArticle Published on 2022-09-012022-11-15 Journal: Hormones (Athens, Greece) [Category] COVID19(2023년), SARS, 진단, [키워드] anti-CD20 antibody response against Antibody titer appear Autoimmune disorders cancers cascade cell-mediated immune comparable disease dose elevated Glucocorticoids Hematological malignancies immune response Immunocompromised Immunosuppressed Immunosuppression individual induce inhibitor methotrexate MMF monoclonal antibody MOST mRNA mRNA SARS-CoV-2 vaccines. neutralizing antibody non-responder Patient proportion Protein Rapamycin recipient S protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Signaling solid cancers solid organ transplant suggested the SARS-CoV-2 the SARS-CoV-2 virus third dose transplantation Treatment Vaccine Vaccines variety while [DOI] 10.1007/s42000-022-00365-y PMC 바로가기
A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipientsBNT162b2 mRNA 백신의 세 번째 접종은 간 이식 환자의 면역 반응을 크게 향상시킵니다Article Published on 2022-09-012022-09-12 Journal: Journal of hepatology [Category] Fulltext, MERS, 진단, [키워드] Adverse adverse effect adverse effects age Anti-RBD IgG anti-SARS-CoV-2 antibody Antibody Response binding domain BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine Booster vaccine cellular immune responses cellular response center correlated determine dose doses Effect evaluate evaluated Factor fatigue Follow-up geometric humoral humoral immune response IgG immune immune response Immunity Immunosuppression immunosuppressive medications IMPROVE inhibitor liver liver transplant recipients local pain majority male median age Mild monotherapy neutralizing antibody Older age Patient predict RBD recipient recipients reported response Side effect side effects BNT162b2 mRNA vaccine significantly solid organ transplant T-cell the patient third dose Treatment Vaccine vaccine dose [DOI] 10.1016/j.jhep.2022.03.042 PMC 바로가기 [Article Type] Article
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccineArticle Published on 2022-09-012022-10-05 Journal: Vaccine [Category] SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] Antibody Response approved BNT162b2 booster booster dose clinical trial comparable CoronaVac coronavirus disease Coverage COVID-19 COVID-19 vaccine Delta diarrhea dose elicited groups headache healthcare healthy heterologous vaccine Inactivated vaccine joint mRNA mRNA vaccine mRNA-1273 vaccine omicron Omicron variant Pain pandemic reactogenicity reduced Reduced dose Result significant difference Standard dose the SARS-CoV-2 third dose Vaccine World Health Organization [DOI] 10.1016/j.vaccine.2022.08.033 [Article Type] Article
Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine dosesArticle Published on 2022-08-172022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] adaptive Administered antibody Asymptomatic BNT162b2 Breakthrough infection breakthrough infections cellular Cohort COVID-19 COVID-19 pandemic declined determine dose effective Follow-up healthcare humoral humoral immune response Hybrid immunity IgG immune immune response Immunity Inclusion increase in individual knowledge Longitudinal assessment Mild mRNA vaccine mRNA-1273 naïve naïve individual naïve individuals neutralization neutralizing antibody peak level Prevent reached reported SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2-specific T cells second dose T cell T cells third dose triggered vaccination Vaccine Viral antigen [DOI] 10.3389/fimmu.2022.981350 PMC 바로가기
A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 VaccinemRNA COVID-19 백신의 추가 용량으로 예방 접종을 받은 요양원 거주자 사이에서 SARS-CoV-2 발생Article Published on 2022-08-012022-09-11 Journal: Journal of community health [Category] SARS, 변종, [키워드] activities administration B.1.617.2 booster dose caused collected data COVID-19 COVID-19 complications daily living Delta delta variant died dose Effectiveness elderly healthcare worker home hospitalisation Impact Impact of vaccination increased risk Independence individual infected with SARS-CoV-2 interactions Italy median age Mild disease mild symptoms mRNA Nursing nursing home occurred outbreak required resident SARS-CoV-2 severe disease third dose Vaccine variant [DOI] 10.1007/s10900-022-01082-8 PMC 바로가기 [Article Type] Article